Bumetanide
Bumex (bumetanide) is a small molecule pharmaceutical. Bumetanide was first approved as Bumex on 1983-02-28. It is used to treat ascites, chronic kidney failure, edema, heart failure, and hypertension amongst others in the USA. The pharmaceutical is active against solute carrier family 12 member 1. In addition, it is known to target G-protein coupled receptor 35 and solute carrier family 12 member 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
| respiratory tract diseases | D012140 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Bumex (generic drugs available since 1994-10-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bumetanide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BUMEX | Validus Pharmaceuticals | N-018225 RX | 1983-02-28 | 3 products, RLD |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bumetanide | NDA authorized generic | 2023-06-16 |
| bumex | New Drug Application | 2021-01-26 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| ascites | HP_0001541 | D001201 | R18 |
| chronic kidney failure | EFO_0003884 | D007676 | N18.6 |
| edema | — | D004487 | R60.9 |
| heart failure | EFO_0003144 | D006333 | I50 |
| hypertension | EFO_0000537 | D006973 | I10 |
| liver cirrhosis | EFO_0001422 | D008103 | K74.0 |
| nephrotic syndrome | EFO_0004255 | D009404 | N04 |
| pulmonary edema | EFO_1001134 | D011654 | J81 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03C: High-ceiling diuretics
— C03CA: Sulfonamides, high-ceiling diuretics, plain
— C03CA02: Bumetanide
— C03CB: Sulfonamides and potassium in combination, high-ceiling diruetics, excluding thiazides
— C03CB02: Bumetanide and potassium
— C03E: Diuretics and potassium-sparing agents in combination
— C03EB: High-ceiling diuretics and potassium-sparing agents
— C03EB02: Bumetanide and potassium-sparing agents
HCPCS
Code | Description |
|---|---|
| S0171 | Injection, bumetanide, 0.5 mg |
Clinical
Clinical Trials
221 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | — | 1 | — | 2 | 8 | 11 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 2 | 2 | 1 | 5 | 10 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | — | 1 | 7 | 9 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 2 | 1 | 3 | 7 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | 4 | 5 |
| Coronary disease | D003327 | — | 1 | — | 1 | 2 | 4 | ||
| Sudden death cardiac | D016757 | EFO_0004278 | — | — | — | 1 | 3 | 4 | |
| Ischemic stroke | D000083242 | — | — | — | 2 | — | 2 | ||
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | 1 | 1 | 2 |
| Lung neoplasms | D008175 | C34.90 | — | — | — | 1 | 1 | 2 |
Show 14 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | 2 | 3 | — | 18 | 22 |
| Vitamin a deficiency | D014802 | EFO_1001237 | E50 | — | 2 | 2 | — | 3 | 7 |
| Healthy volunteers/patients | — | 1 | — | 1 | — | 4 | 6 | ||
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | 3 | 4 |
| Dilated cardiomyopathy | D002311 | EFO_0000407 | I42.0 | — | 1 | 1 | — | 2 | 4 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | 2 | — | 1 | 3 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | 1 | — | — | 2 | |
| Neoplasms | D009369 | C80 | — | — | 1 | — | 1 | 2 | |
| Mitral valve insufficiency | D008944 | HP_0001653 | — | — | 1 | — | 1 | 2 | |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | 5 | 6 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | 3 | 4 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | — | — | 3 | 4 |
| Peripheral arterial disease | D058729 | EFO_0004265 | 1 | 1 | — | — | — | 1 | |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | 1 | — | — | — | 1 |
| Urologic neoplasms | D014571 | C64-C68 | — | 1 | — | — | — | 1 | |
| Anterior wall myocardial infarction | D056988 | EFO_1000812 | — | 1 | — | — | — | 1 | |
| Noise-induced hearing loss | D006317 | EFO_1001254 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | 1 | 2 |
| Respiratory tract infections | D012141 | J06.9 | 1 | — | — | — | 1 | 2 | |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | — | — | — | 1 | 2 |
| Chronic pain | D059350 | HP_0012532 | 1 | — | — | — | 1 | 2 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 1 | 2 |
| Juvenile arthritis | D001171 | EFO_0002609 | M08 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 5 | 5 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 5 | 5 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 4 | 4 |
| Depression | D003863 | F33.9 | — | — | — | — | 4 | 4 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 3 | 3 |
| Emphysema | D004646 | EFO_0000464 | J43 | — | — | — | — | 3 | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 2 | 2 |
| Pulmonary atelectasis | D001261 | J98.1 | — | — | — | — | 2 | 2 | |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 2 | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 2 | 2 |
Show 110 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BUMETANIDE |
| INN | bumetanide |
| Description | Bumetanide is a member of the class of benzoic acids that is 4-phenoxybenzoic acid in which the hydrogens ortho to the phenoxy group are substituted by butylamino and sulfamoyl groups. Bumetanide is a diuretic, and is used for treatment of oedema associated with congestive heart failure, hepatic and renal disease. It has a role as a diuretic and an EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor. It is a sulfonamide, an amino acid and a member of benzoic acids. |
| Classification | Small molecule |
| Drug class | diuretics (piretanide type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 28395-03-1 |
| RxCUI | 1808 |
| ChEMBL ID | CHEMBL1072 |
| ChEBI ID | 3213 |
| PubChem CID | 2471 |
| DrugBank | DB00887 |
| UNII ID | 0Y2S3XUQ5H (ChemIDplus, GSRS) |
Target
Agency Approved
SLC12A1
SLC12A1
Organism
Homo sapiens
Gene name
SLC12A1
Gene synonyms
NKCC2
NCBI Gene ID
Protein name
solute carrier family 12 member 1
Protein synonyms
bumetanide-sensitive cotransporter type 1, Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2, Kidney-specific Na-K-Cl symporter, Na-K-2Cl cotransporter, Na-K-2Cl cotransporter 2, solute carrier family 12 (sodium/potassium/chloride transporter), member 1, solute carrier family 12 (sodium/potassium/chloride transporters), member 1
Uniprot ID
Mouse ortholog
Slc12a1 (20495)
solute carrier family 12 member 1 (P55014)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,092 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bumetanide, Bumex
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
66 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more